New pill targets 'Undruggable' cancer mutation in first human tests
NCT ID NCT06667544
Summary
This is the first study in people to test a new oral medication called RNK08954. It aims to find a safe and effective dose for adults with advanced solid tumors that have a specific genetic change called a KRAS G12D mutation. The study will also see if the drug can help control the cancer in patients who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS G12D MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, Guangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Chest Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.